Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, et al. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open Lancet Oncol 2025 Aug 27:S1470-2045(25)00358.
PMID: 40885199